Adventrx Pharmaceuticals

Company Website

6725 Mesa Ridge Road, Suite 100
San Diego, CA 92121

Sourcebook Data

View all the companies in Biomed & Biotech Firms - Publicly Traded*

Adventrx Pharmaceuticals

Market Cap as of 7/03/2014

Market Cap as of 07/02/2013

Market Cap as of 06/26/2012

$23,037,144

Market Cap as of 01/04/2012

$29,106,580

Market Cap as of 06/20/2011

$70,398,790

Market Cap as of 01/06/2011

$43,074,560

Exchange and Ticker Symbol

NYSE: ANX

Fields of Research

Focuses on developing proprietary product candidates

Major Products

ANX-188, ANX-514

Executives

Brian Culley

  • Chief Executive Officer

Related News

Articles

Adventrx engages Theradex Systems to manage clinical study

Adventrx Pharmaceuticals Inc. (NYSE: ANX) Tuesday announced that it has engaged Theradex Systems Inc., a contract research organization with 30 years of experience, to manage the company's upcoming phase 3 study of ANX-188 (purified poloxamer 188) in sickle cell disease.

ADVENTRX Pharmaceuticals has new CFO, SVP

ADVENTRX Pharmaceuticals Inc. (NYSE: ANX) has promoted Brandi L. Roberts to chief financial officer and senior vice president for the company, effective immediately.

Adventrx changes name to Mast Therapeutics

San Diego-based Adventrx Pharmaceuticals Inc. (NYSE: ANX) announced that its corporate name will be Mast Therapeutics Inc. and its ticker symbol will change to MSTX, effective March 11.

Subscribe Today!